Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b open-label zipalertinib trial in EGFR-mutant advanced non-small cell lung cancer
2023-503865-48-00Phase 2Authorised
- Sponsor
- Taiho Oncology
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, open-label trial of zipalertinib in non-small cell lung cancer (NSCLC) (4 cohorts), sponsored by Taiho Oncology. Primary endpoint: Objective response rate. Planned start Feb 2024; status: authorised.
02
Drugs
zipalertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-503865-48-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503865-48-00.